No Data
No Data
No Data
No Data
No Data
聯康生物科技集團:年報2023
Futu NewsApr 23 04:44 ET · Announcements
Liankang Biotechnology Group (00690) announced its 2023 annual results. Revenue reached a record high, with profit reaching HK$70.9 million, a significant increase of 84.04% over the previous year
According to the Zhitong Finance App, Liankang Biotechnology Group (00690) announced its annual results for the year ended December 31, 2023. The Group's revenue reached a record high, reaching approximately HK$484.7 million, an increase of 10.1% year-on-year. The sales performance of Pina Generic Gin Peptides was exceptional, with year-on-year increases of 15.0% and 9.54%, respectively. Profit during the year reached approximately HK$70.9 million, a significant year-on-year increase of 84.04%, making it an important milestone for a research biopharmaceutical company. General and administrative expenses as a percentage of revenue decreased from 10.7% to 9.8% during the year due to the Group's continued internal growth
Zhitong FinanceMar 27 11:14 ET
UNI-BIO GROUP: ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Futu NewsMar 27 10:34 ET · Announcements
Liankang Biotechnology Group (00690.HK) will hold a board meeting on March 27 to approve the annual results
Gelonghui March 15 | Liankang Biotechnology Group (00690.HK) issued an announcement. The company's board of directors meeting will be held on March 27, 2024 to review and approve the Group's annual results and announcements for the year ended December 31, 2023, and consider the proposal to pay a final dividend (if any).
Gelonghui FinanceMar 15 04:52 ET
UNI-BIO GROUP: DATE OF BOARD MEETING
Futu NewsMar 15 04:35 ET · Announcements
Uni-Bio Science's Profit to Climb in 2023
Uni-Bio Science Group (HKG:0690) expects to book a profit attributable to the owners of not less than HK$60 million for the financial year 2023, higher than HK$38.5 million a year earlier. The biotech
MT NewswiresFeb 14 00:26 ET
No Data
No Data